<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03920059</url>
  </required_header>
  <id_info>
    <org_study_id>FDCC lupus</org_study_id>
    <nct_id>NCT03920059</nct_id>
  </id_info>
  <brief_title>Fixed-dose Versus Concentration-controlled Mycophenolate Mofetil for the Treatment of Active Lupus Nephritis</brief_title>
  <official_title>A Randomized Open-label Study of Fixed-dose Versus Concentration-controlled Mycophenolate Mofetil for the Treatment of Active Lupus Nephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Berlin Pharmaceutical Industry</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized open-label study of fixed-dose versus concentration-controlled mycophenolate&#xD;
      mofetil for treatment of active lupus nephritis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow recruitment rate&#xD;
  </why_stopped>
  <start_date type="Actual">August 20, 2019</start_date>
  <completion_date type="Actual">January 30, 2020</completion_date>
  <primary_completion_date type="Actual">January 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate at 48 week of therapy</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mycophenolic acid trough levels</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MPA-area under the curve (AUC) 0-4 hour at 12 week</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C3 levels</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine IP-10 levels</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-dsDNA</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse free survival at 96, 144 and 240 week</measure>
    <time_frame>96, 144 and 240 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eGFR at 96, 144 and 240 week</measure>
    <time_frame>96, 144 and 240 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression to CKD stage 3 or more at 96, 144 and 240 week</measure>
    <time_frame>96, 144 and 240 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End stage renal disease at 96, 144 and 240 week</measure>
    <time_frame>96, 144 and 240 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Lupus Nephritis</condition>
  <arm_group>
    <arm_group_label>FD arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>MMF will be prescribed at a starting dose of 1.5 g/day and increased to 2 g/day at week 4 (if body weight ≥ 45 kg) and continue the same dose until week 24. After week 24, MMF will be lowered to 1.5 g/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MMF will be prescribed at a starting dose of 1.5 g/day. MPA-C0 (trough) level will be measured weekly and MMF dose will be increased by 500 mg/day every week until the MPA-C0 level ≥ 3 mg/L or the MMF dosage is 3000 mg/day. After achieving the targeted MPA-C0 level, the MMF dose adjustment will be allowed only if the MPA-C0 levels are lower than 3 mg/L for two consecutive monitoring visits. After week 12, MMF will be maintained at the same dose until week 48</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Description Each capsule contains Mycophenolate mofetil 250 mg. Presentation / Packing Cap 250 mg (white to off white powder, light blue/peach hard gelatin, imprinting with &quot;MMF&quot; on cap and &quot;250&quot; on body) x 10 x 10's.&#xD;
Storage Store below 30 degree Celcius.</description>
    <arm_group_label>CC Arm</arm_group_label>
    <arm_group_label>FD arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-65 year&#xD;
&#xD;
          -  Diagnosis of SLE according to ACR criteria. At least 4 criteria must have been present&#xD;
             for the diagnosis of SLE&#xD;
&#xD;
          -  Active lupus nephritis (both new and flare patients can be included) defined as:&#xD;
&#xD;
               -  Within 16 weeks of randomization, had Biopsy-proven ISN class III or IV [exclude&#xD;
                  III(c), IV-S(c) and IV-G(c). Patients are permitted to have co-existing class V&#xD;
                  and&#xD;
&#xD;
               -  At screening day, has urine protein creatinine ratio (UPCR) or 24-hour urinary&#xD;
                  protein ≥ 1.0 g/g or g/day&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Child-bearing age women who refuse to use effective birth-control&#xD;
&#xD;
          -  Poor compliance&#xD;
&#xD;
          -  Estimated-GFR &lt; 20 mL/min/1.73 m2&#xD;
&#xD;
          -  Crescentic glomeruli more than 30 percent&#xD;
&#xD;
          -  Severe extra-renal involvement of SLE&#xD;
&#xD;
          -  History of severe allergic reactions or adverse effects to MMF&#xD;
&#xD;
          -  Uncontrolled concomitant disease&#xD;
&#xD;
          -  Known active, clinically significant infection of any kind&#xD;
&#xD;
          -  History of serious recurrent or chronic infection&#xD;
&#xD;
          -  History of malignancy (except basal cell carcinoma, squamous cell carcinoma of the&#xD;
             skin or carcinoma in situ of the cervix that has been excised and cured)&#xD;
&#xD;
          -  Concomitant conditions which has required treatment with systemic corticosteroid&#xD;
             (excluding topical or inhaled steroids) at any time in the 52 weeks prior to screening&#xD;
&#xD;
          -  Treatment with more than 1 g cyclophosphamide within the past 24 weeks&#xD;
&#xD;
          -  Receipt more than 3 g of IV pulse methylprednisolone within the past 12 weeks&#xD;
&#xD;
          -  Receipt prednisolone more than 30 mg/day for longer than 30 days within the past 12&#xD;
             weeks&#xD;
&#xD;
          -  Treatment with MMF at ≥ 1.5 g/day for over 4 weeks within the past 12 weeks&#xD;
&#xD;
          -  On treatment with Tacrolimus or Cyclosporine on the day of screening&#xD;
&#xD;
          -  Treatment with any biologic B-cell depleting therapy (e.g. anti CD-20, anti CD 22)&#xD;
             within 52 weeks&#xD;
&#xD;
          -  Receiving concomitant medication interfering PK of MPA&#xD;
&#xD;
               -  Cholestyramine&#xD;
&#xD;
               -  Rifampin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>King Chulalongkorn Memorial Hospital</name>
      <address>
        <city>Bangkok</city>
        <state>Please Select</state>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 1, 2019</study_first_submitted>
  <study_first_submitted_qc>April 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2019</study_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Yingyos Avihingsanon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

